99
Participants
Start Date
May 13, 2021
Primary Completion Date
April 5, 2024
Study Completion Date
January 30, 2025
Tildrakizumab
PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Placebo
PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
Premier Dermatology (Site 47), Kogarah
St George Dermatology & Skin Cancer Centre (Site 45), Kogarah
Skin Health Institute Inc. (Site 43), Carlton
Veracity Clinical Research/ Specialist Connect(Site 44), Woolloongabba
North Eastern Health Specialists (Site 46), Campbelltown
Fremantle Dermatology (Site 40), Fremantle
Forest Hills Dermatology Group (Site 04), Forest Hills
Florida Academic Centers Research and Education, LLC (Site 21), Coral Gables
Renstar Medical Research (Site 23), Ocala
Center for Clinical Studies (Site 11), Houston
Center for Clinical Studies Cypress (Site 17), Cypress
Progressive Clinical Research (Site 27), San Antonio
Dermatology Research Associates (Site 09), Los Angeles
Clinical Science Institute (Site 14), Santa Monica
California Dermatology & CRI (Site 18), Encinitas
First OC Dermatology (Site 07), Fountain Valley
Clinical Partners, LLC (Site 08), Johnston
Sun Pharmaceutical Industries Limited
INDUSTRY